CL2011002807A1 - Mezcla farmaceutica comprimible que comprende cristales de un farmaco con tamaño de particulas inferior a 40 um y un adyuvante de la disolucion; procedimiento para preparar un vehiculo de administracion para un farmaco que incluye moler una premezcla de cristales de farmaco y un adyuvante de la disolucion. - Google Patents

Mezcla farmaceutica comprimible que comprende cristales de un farmaco con tamaño de particulas inferior a 40 um y un adyuvante de la disolucion; procedimiento para preparar un vehiculo de administracion para un farmaco que incluye moler una premezcla de cristales de farmaco y un adyuvante de la disolucion.

Info

Publication number
CL2011002807A1
CL2011002807A1 CL2011002807A CL2011002807A CL2011002807A1 CL 2011002807 A1 CL2011002807 A1 CL 2011002807A1 CL 2011002807 A CL2011002807 A CL 2011002807A CL 2011002807 A CL2011002807 A CL 2011002807A CL 2011002807 A1 CL2011002807 A1 CL 2011002807A1
Authority
CL
Chile
Prior art keywords
drug
crystals
dissolution aid
premix
preparing
Prior art date
Application number
CL2011002807A
Other languages
English (en)
Inventor
Eric R First
Ashish B Schmitz Guido Petaway Hicksonstepahie Tong Hung Huar Patel
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43062708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002807(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CL2011002807A1 publication Critical patent/CL2011002807A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mezcla para conformar un comprimido que comprende cristales de un ingrediente medicinalmente activo y un adyuvante de disolución; y su procedimiento de preparación.
CL2011002807A 2009-05-11 2011-11-10 Mezcla farmaceutica comprimible que comprende cristales de un farmaco con tamaño de particulas inferior a 40 um y un adyuvante de la disolucion; procedimiento para preparar un vehiculo de administracion para un farmaco que incluye moler una premezcla de cristales de farmaco y un adyuvante de la disolucion. CL2011002807A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/387,977 US11135188B2 (en) 2009-05-11 2009-05-11 Method and composition to improve absorption of therapeutic agents

Publications (1)

Publication Number Publication Date
CL2011002807A1 true CL2011002807A1 (es) 2012-06-15

Family

ID=43062708

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002807A CL2011002807A1 (es) 2009-05-11 2011-11-10 Mezcla farmaceutica comprimible que comprende cristales de un farmaco con tamaño de particulas inferior a 40 um y un adyuvante de la disolucion; procedimiento para preparar un vehiculo de administracion para un farmaco que incluye moler una premezcla de cristales de farmaco y un adyuvante de la disolucion.

Country Status (15)

Country Link
US (1) US11135188B2 (es)
EP (1) EP2429502B1 (es)
AR (1) AR076864A1 (es)
BR (1) BRPI1013509A2 (es)
CA (1) CA2761678A1 (es)
CL (1) CL2011002807A1 (es)
CO (1) CO6460753A2 (es)
EA (1) EA201171399A1 (es)
HU (1) HUE043173T2 (es)
MX (1) MX2011011928A (es)
PL (1) PL2429502T3 (es)
PT (1) PT2429502T (es)
SI (1) SI2429502T1 (es)
UY (1) UY32624A (es)
WO (1) WO2010132095A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872317B2 (en) 2019-02-27 2024-01-16 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetominophen and ibuprofen

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
EP2953617B1 (en) * 2013-02-06 2019-10-02 Hermes Arzneimittel GmbH Pharmaceutical compositions incorporating low-dose drugs
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
PT3154528T (pt) 2014-06-11 2023-06-22 SpecGx LLC Composições secas por pulverização possuindo diferentes perfis de dissolução e processos para a sua preparação
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CA3201462A1 (en) * 2020-11-13 2022-05-19 Bayer Healthcare Llc Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191225486A (en) 1912-11-06 1913-04-24 Herbert Sefton-Jones Manufacture and Production of Improved Pharmaceutical Preparations.
US2293359A (en) 1941-01-08 1942-08-18 Quisling Sverre Acetyl salicylic acid preparation
FI89004C (fi) 1988-02-16 1993-08-10 Pertti J Neuvonen Anvaendning av tillsatsmedel foer oekning av absorptionshastigheten av laekemedel i orala laekemedelspreparat
RU2099058C1 (ru) 1992-06-15 1997-12-20 Институт химии твердого тела и переработки минерального сырья СО РАН Способ получения твердой быстрорастворимой дисперсной системы, содержащей ацетилсалициловую кислоту
US5665388A (en) 1995-11-13 1997-09-09 Health Corporation Method for preparation of an alkaline and aspirin combination compound
ZA987800B (en) 1997-08-27 1999-06-09 Hexal Ag Pharmaceutical composition of meloxicam
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
RU2170582C1 (ru) 2000-02-17 2001-07-20 Институт химии твердого тела и механохимии СО РАН Способ получения быстрорастворимой таблетированной формы ацетилсалициловой кислоты
EP1744757A4 (en) 2004-05-04 2009-04-22 Equitech Corp IMPROVED ENHANCED COMPOSITION
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
ES2450648T3 (es) * 2004-06-29 2014-03-25 Takeda Pharma A/S Fabricación de composiciones farmacéuticas con liberación rápida de fármacos insolubles en agua y composiciones farmacéuticas obtenidas mediante el procedimiento de la invención
EP2417969A1 (en) * 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9757455B2 (en) 2005-11-28 2017-09-12 Johnson & Johnson Consumer Inc. Oral therapeutic compound delivery system
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872317B2 (en) 2019-02-27 2024-01-16 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetominophen and ibuprofen

Also Published As

Publication number Publication date
EP2429502A4 (en) 2012-10-24
US20100286100A1 (en) 2010-11-11
WO2010132095A1 (en) 2010-11-18
PL2429502T3 (pl) 2019-07-31
EP2429502A1 (en) 2012-03-21
EA201171399A1 (ru) 2012-05-30
US11135188B2 (en) 2021-10-05
PT2429502T (pt) 2019-03-29
WO2010132095A8 (en) 2011-07-07
CO6460753A2 (es) 2012-06-15
MX2011011928A (es) 2011-12-06
AR076864A1 (es) 2011-07-13
HUE043173T2 (hu) 2019-08-28
CA2761678A1 (en) 2010-11-18
UY32624A (es) 2010-12-31
BRPI1013509A2 (pt) 2016-04-05
EP2429502B1 (en) 2018-12-26
SI2429502T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
CL2011002807A1 (es) Mezcla farmaceutica comprimible que comprende cristales de un farmaco con tamaño de particulas inferior a 40 um y un adyuvante de la disolucion; procedimiento para preparar un vehiculo de administracion para un farmaco que incluye moler una premezcla de cristales de farmaco y un adyuvante de la disolucion.
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
IL218165A (en) Stable Pharmaceutical Formulations Highly Concentrated to Provide Subcutaneous Active Pharmaceutical Antibody against CD20
WO2008146178A3 (en) A novel tablet dosage form
MX343867B (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
MX363495B (es) Proceso de manufacturacion de una forma de dosificacion multifasica de rapida disolucion liofilizada.
MX2011011829A (es) Composicion para suministro sostenido de farmaco que comprende un aglutinante geopolimerico.
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
PH12014501408A1 (en) Immediate release multi unit pellet system
MX2014008283A (es) Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
TN2015000135A1 (en) Modified release formulations for oprozomib
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
BR112013029199A2 (pt) sistema de distribuição de fármacos, dispositivo de distribuição de dois fármacos, método para preparar o mesmo, comprimido para administração sublingual de um ingrediente ativo, e, método para a administração de um ingrediente ativo a um indivíduo
MX362151B (es) Dispersion solida de un modulador selectivo de los receptores de progesterona.
IN2015DN01738A (es)
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
WO2011095801A3 (en) Liquid pharmaceutical composition for buccal administration comprising morphine
WO2014013505A3 (en) Amorphous vildagliptin
NZ702849A (en) Genotype- or phenotype-based drug formulation
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
UA97524C2 (ru) Лекарственный препарат противосудорожного действия топиромата в форме таблеток и его кристаллический состав